Brief: Talaris Therapeutics And Tourmaline Bio Announce Merger Agreement

Tourmaline Bio

22/06/2023 12:39

June 22 (Reuters) - Talaris Therapeutics Inc  TALS.O :
    * TALARIS THERAPEUTICS AND TOURMALINE BIO ANNOUNCE MERGER
AGREEMENT
    * TALARIS THERAPEUTICS INC: TALARIS STOCKHOLDERS EXPECTED TO
RECEIVE APPROXIMATELY $3.43 PER TALARIS SHARE
    * TALARIS THERAPEUTICS - COMBINED COMPANY WILL OPERATE UNDER
NAME
TOURMALINE BIO, INC. AND TRADE ON NASDAQ UNDER TICKER SYMBOL
"TRML."
    * TALARIS THERAPEUTICS INC - MERGER TO CREATE NASDAQ-LISTED,
LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY
    * TALARIS THERAPEUTICS - ANTICIPATES MAKING A CASH DIVIDEND
OF UP
TO ABOUT $64.8 MILLION TO ITS STOCKHOLDERS PRIOR TO CLOSING OF
MERGER
    * TALARIS THERAPEUTICS INC - MERGER HAS BEEN UNANIMOUSLY
APPROVED
BY BOARD OF DIRECTORS OF BOTH COMPANIES
    * TALARIS THERAPEUTICS INC - COMBINED COMPANY WILL BE LED BY
CURRENT MEMBERS OF TOURMALINE LEADERSHIP TEAM
    * TALARIS THERAPEUTICS - TOURMALINE STOCKHOLDERS IMMEDIATELY
PRIOR
TO MERGER ARE EXPECTED TO OWN ABOUT 78.7% OF COMBINED CO
    * TALARIS THERAPEUTICS INC - BOARD OF DIRECTORS OF COMBINED
COMPANY WILL BE COMPOSED OF SEVEN BOARD MEMBERS

Source text for Eikon:  ID:nGNX8lVznY 
Further company coverage:  TALS.O 

 ((reuters.briefs@thomsonreuters.com;))